Los Angeles Capital Management
CTMX icon

Los Angeles Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Los Angeles Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-87,723
Closed -$447K – 1413
2021
Q3 		$447K Buy
87,723
+16,000
+22% +$85.7K ﹤0.01% 1109
2021
Q2 		$454K Buy
71,723
+3,190
+5% +$24.8K ﹤0.01% 1221
2021
Q1 		$530K Sell
68,533
-28,016
-29% -$222K ﹤0.01% 1197
2020
Q4 		$632K Sell
96,549
-3,685
-4% -$26.3K ﹤0.01% 1116
2020
Q3 		$667K Buy
100,234
+4,070
+4% +$30.2K ﹤0.01% 974
2020
Q2 		$801K Buy
96,164
+57,500
+149% +$534K ﹤0.01% 932
2020
Q1 		$297K Buy
+38,664
New +$270K ﹤0.01% 1055
2019
Q2 		– Sell
-10,057
Closed -$108K – 1357
2019
Q1 		$108K Sell
10,057
-10,680
-52% -$158K ﹤0.01% 1334
2018
Q4 		$313K Sell
20,737
-215
-1% -$3.19K ﹤0.01% 1086
2018
Q3 		$388K Buy
20,952
+4,520
+28% +$103K ﹤0.01% 1169
2018
Q2 		$376K Buy
16,432
+430
+3% +$11K ﹤0.01% 1221
2018
Q1 		$455K Sell
16,002
-390
-2% -$11.1K ﹤0.01% 1062
2017
Q4 		$346K Buy
+16,392
New +$340K ﹤0.01% 1150

Other funds holding CTMX

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Los Angeles Capital Management's CTMX Position: Q4 2021 in Review

Los Angeles Capital Management sold out of CytomX Therapeutics (CTMX) in Q4 2021, closing a stake of 87,723 shares — an estimated $447K sold.

Los Angeles Capital Management first reported a position in CTMX in Q4 2017 and held it in 13 quarters. The position peaked at $801K in Q2 2020. 110 funds tracked by Wall St. Rank hold CTMX as of Q4 2021.

  • Los Angeles Capital Management reported no remaining CytomX Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Los Angeles Capital Management sold 87,723 CytomX Therapeutics shares in Q4 2021, an estimated $447K.
  • Los Angeles Capital Management first reported a position in CytomX Therapeutics in Q4 2017 and held it in 13 quarters.
  • Los Angeles Capital Management's CytomX Therapeutics position peaked at $801K in Q2 2020.
  • 110 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2021.

Based on Los Angeles Capital Management's 13F filing for Q4 2021, filed 3 Feb 2022.